PMC:7195088 / 994-1301
Annnotations
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T3 | 181-182 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T4 | 253-258 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 253-258 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T2 | 259-268 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T3 | 273-296 | Chemical | denotes | anti-inflammatory drugs | http://purl.obolibrary.org/obo/CHEBI_35472 |
| T4 | 291-296 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T11 | 28-35 | Sentence | denotes | Content |
| T12 | 36-229 | Sentence | denotes | The available literature and the authors' frontline-based opinion are summarized in brief narrative answers to selected clinical questions, with a conclusive statement provided for each answer. |
| T13 | 231-243 | Sentence | denotes | Implications |